| |
| |
|
| Insider
Information: |
Higgins John L |
| Relationship: |
Director |
| City: |
Palo Alto |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
3 |
|
| Direct
Shares |
2,806,928 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$49,065,023 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
2,806,928 |
|
|
| Total
Value |
$49,065,023 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
11
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
6
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -34.7%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Ligand Pharmaceuticals Inc |
LGND |
Director |
2022-12-28 |
417,695 |
2007-02-01 |
0 |
Premium* |
|
|
Techne Corp |
TECH |
Director |
2024-05-14 |
36,608 |
2013-10-31 |
0 |
Premium* |
|
|
OmniAb, Inc |
OABI |
Director |
2024-01-30 |
2,352,625 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
165 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-11-16 |
4 |
S |
$142.53 |
$750,991 |
D/D |
(5,269) |
143,542 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Director |
– • – |
2022-12-28 |
4 |
D |
$66.29 |
$350,608 |
D/D |
(5,289) |
417,695 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-08-08 |
4 |
OE |
$21.00 |
$115,143 |
D/D |
5,483 |
144,654 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-08-08 |
4 |
AS |
$125.00 |
$685,375 |
D/D |
(5,483) |
139,171 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-02-15 |
4 |
D |
$123.68 |
$732,557 |
D/D |
(5,923) |
340,593 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2010-02-17 |
4 |
B |
$1.67 |
$10,020 |
D/D |
6,000 |
439,276 |
2.81 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2012-02-09 |
4/A |
A |
$0.00 |
$0 |
D/D |
6,000 |
95,275 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2016-03-08 |
4 |
OE |
$21.00 |
$126,000 |
D/D |
6,000 |
125,664 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-03-06 |
4 |
A |
$0.00 |
$0 |
D/D |
6,015 |
110,401 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
D |
$157.18 |
$981,118 |
D/D |
(6,242) |
96,458 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-08-19 |
4 |
OE |
$16.14 |
$105,814 |
D/D |
6,556 |
116,581 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-12-20 |
4 |
D |
$105.87 |
$714,517 |
D/D |
(6,749) |
153,614 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2019-01-23 |
4 |
D |
$111.78 |
$756,192 |
D/D |
(6,765) |
126,090 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2021-01-25 |
4 |
D |
$156.01 |
$1,160,870 |
D/D |
(7,441) |
243,422 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
7,928 |
104,386 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2013-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
120,025 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-02-12 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
119,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-05-09 |
4 |
OE |
$21.92 |
$175,360 |
D/D |
8,000 |
348,593 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
President & CEO |
• • – |
2014-01-21 |
4 |
OE |
$21.00 |
$189,000 |
D/D |
9,000 |
111,099 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2018-02-15 |
4 |
AS |
$157.03 |
$1,413,279 |
D/D |
(9,000) |
102,700 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Director |
– • – |
2023-05-23 |
4 |
OE |
$3.68 |
$33,120 |
D/D |
9,000 |
2,471,686 |
0 |
- |
|
| OABI |
OmniAb, Inc |
Director |
– • – |
2023-05-23 |
4 |
S |
$4.05 |
$36,450 |
D/D |
(9,000) |
2,462,686 |
0 |
% |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-01-26 |
4 |
D |
$113.68 |
$1,050,744 |
D/D |
(9,243) |
349,018 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2022-11-30 |
4 |
D |
$72.90 |
$714,639 |
D/D |
(9,803) |
416,928 |
0 |
- |
|
| LGND |
Ligand Pharmaceuticals In... |
Chief Executive Officer |
• • – |
2017-12-28 |
4 |
A |
$0.00 |
$0 |
D/D |
9,965 |
151,249 |
0 |
- |
|
165 Records found
|
|
Page 4 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
